Xizang Haisco Pharmaceutical Group Co Ltd (002653) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Xizang Haisco Pharmaceutical Group Co Ltd (002653) has a cash flow conversion efficiency ratio of 0.009x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥39.68 Million ≈ $5.81 Million USD) by net assets (CN¥4.23 Billion ≈ $618.26 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Review Xizang Haisco Pharmaceutical Group Co Lt free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.
Xizang Haisco Pharmaceutical Group Co Ltd - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how Xizang Haisco Pharmaceutical Group Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see 002653 market cap for the company's overall valuation and market capitalisation.
Xizang Haisco Pharmaceutical Group Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Xizang Haisco Pharmaceutical Group Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
First Horizon Corporation
NYSE:FHN
|
0.029x |
|
MOL Nyrt.
BUD:MOL
|
0.046x |
|
VERBUND AG
VI:VER
|
0.039x |
|
Evercore Partners Inc
NYSE:EVR
|
-0.108x |
|
Regal Beloit Corporation
NYSE:RRX
|
0.024x |
|
Littelfuse Inc
NASDAQ:LFUS
|
0.031x |
|
Datang International Power Generation Co Ltd Class A
SHG:601991
|
0.290x |
|
Hong Leong Bank Bhd
KLSE:5819
|
0.055x |
Annual Cash Flow Conversion Efficiency for Xizang Haisco Pharmaceutical Group Co Ltd (2008–2025)
The table below shows the annual cash flow conversion efficiency of Xizang Haisco Pharmaceutical Group Co Ltd from 2008 to 2025. View 002653 stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥4.29 Billion ≈ $627.44 Million |
CN¥786.00 Million ≈ $115.02 Million |
0.183x | +74.26% |
| 2024-12-31 | CN¥4.20 Billion ≈ $614.92 Million |
CN¥442.05 Million ≈ $64.69 Million |
0.105x | -2.42% |
| 2023-12-31 | CN¥4.17 Billion ≈ $610.28 Million |
CN¥449.58 Million ≈ $65.79 Million |
0.108x | +257.25% |
| 2022-12-31 | CN¥3.13 Billion ≈ $458.49 Million |
CN¥94.55 Million ≈ $13.84 Million |
0.030x | +146.13% |
| 2021-12-31 | CN¥2.92 Billion ≈ $427.32 Million |
CN¥35.80 Million ≈ $5.24 Million |
0.012x | -83.03% |
| 2020-12-31 | CN¥2.85 Billion ≈ $417.74 Million |
CN¥206.21 Million ≈ $30.17 Million |
0.072x | -77.54% |
| 2019-12-31 | CN¥2.38 Billion ≈ $347.78 Million |
CN¥764.26 Million ≈ $111.84 Million |
0.322x | +35.70% |
| 2018-12-31 | CN¥1.99 Billion ≈ $291.83 Million |
CN¥472.61 Million ≈ $69.16 Million |
0.237x | +19.17% |
| 2017-12-31 | CN¥1.97 Billion ≈ $288.32 Million |
CN¥391.81 Million ≈ $57.33 Million |
0.199x | +9.11% |
| 2016-12-31 | CN¥2.25 Billion ≈ $328.53 Million |
CN¥409.20 Million ≈ $59.88 Million |
0.182x | -11.28% |
| 2015-12-31 | CN¥2.16 Billion ≈ $315.58 Million |
CN¥443.03 Million ≈ $64.83 Million |
0.205x | -13.86% |
| 2014-12-31 | CN¥2.11 Billion ≈ $308.37 Million |
CN¥502.57 Million ≈ $73.54 Million |
0.238x | -19.15% |
| 2013-12-31 | CN¥1.93 Billion ≈ $281.97 Million |
CN¥568.41 Million ≈ $83.18 Million |
0.295x | +8.40% |
| 2012-12-31 | CN¥1.71 Billion ≈ $249.91 Million |
CN¥464.75 Million ≈ $68.01 Million |
0.272x | -19.89% |
| 2011-12-31 | CN¥767.76 Million ≈ $112.35 Million |
CN¥260.79 Million ≈ $38.16 Million |
0.340x | -58.11% |
| 2010-12-31 | CN¥453.09 Million ≈ $66.30 Million |
CN¥367.38 Million ≈ $53.76 Million |
0.811x | -70.23% |
| 2009-12-31 | CN¥135.17 Million ≈ $19.78 Million |
CN¥368.21 Million ≈ $53.88 Million |
2.724x | +519.97% |
| 2008-12-31 | CN¥214.95 Million ≈ $31.45 Million |
CN¥94.45 Million ≈ $13.82 Million |
0.439x | -- |
About Xizang Haisco Pharmaceutical Group Co Ltd
Haisco Pharmaceutical Group Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in China. It offers pharmaceutical products in the areas of anesthesia and analgesic, endocrine system, enteral parenteral nutrition, cardiovascular, psychiatric, tumor-related, digestive liver, and other diseases. Haisco Pharmaceutical Group Co., Ltd. has licensing and research c… Read more